Acurx Pharmaceuticals宣布,欧洲药品管理局(EMA)对该公司伊贝扎波司他用于治疗儿童艰难梭菌感染的儿科研究计划给予了积极意见。这一积极意见为该药物在儿科患者中的进一步开发和应用奠定了重要基础。
Acurx Pharmaceuticals宣布,欧洲药品管理局(EMA)对该公司伊贝扎波司他用于治疗儿童艰难梭菌感染的儿科研究计划给予了积极意见。这一积极意见为该药物在儿科患者中的进一步开发和应用奠定了重要基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.